Sulpiride in tardive dyskinesia

Daniel Casey, Jes Gerlach, Hans Simmelsgaard

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Tardive dyskinesia can be suppressed by drugs that block dopaminergic receptors, but often at the cost of a concomitant increase in parkinsonism. Sulpiride (400-2100 mg/day), a selective type-2 dopamine receptor antagonist, was evaluated in a blind, placebo-controlled trial in 11 patients with tardive dyskinesia. It significantly (P

Original languageEnglish (US)
Pages (from-to)73-77
Number of pages5
JournalPsychopharmacology
Volume66
Issue number1
DOIs
StatePublished - Nov 1979

Fingerprint

Sulpiride
Dopamine Agents
Dopamine Antagonists
Parkinsonian Disorders
Placebos
Tardive Dyskinesia

Keywords

  • Dopamine receptors
  • Neuroleptics
  • Parkinsonism
  • Sulpiride
  • Tardive dyskinesia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Casey, D., Gerlach, J., & Simmelsgaard, H. (1979). Sulpiride in tardive dyskinesia. Psychopharmacology, 66(1), 73-77. https://doi.org/10.1007/BF00431993

Sulpiride in tardive dyskinesia. / Casey, Daniel; Gerlach, Jes; Simmelsgaard, Hans.

In: Psychopharmacology, Vol. 66, No. 1, 11.1979, p. 73-77.

Research output: Contribution to journalArticle

Casey, D, Gerlach, J & Simmelsgaard, H 1979, 'Sulpiride in tardive dyskinesia', Psychopharmacology, vol. 66, no. 1, pp. 73-77. https://doi.org/10.1007/BF00431993
Casey D, Gerlach J, Simmelsgaard H. Sulpiride in tardive dyskinesia. Psychopharmacology. 1979 Nov;66(1):73-77. https://doi.org/10.1007/BF00431993
Casey, Daniel ; Gerlach, Jes ; Simmelsgaard, Hans. / Sulpiride in tardive dyskinesia. In: Psychopharmacology. 1979 ; Vol. 66, No. 1. pp. 73-77.
@article{3614c3dbb3e34d41aad63a3046ecefce,
title = "Sulpiride in tardive dyskinesia",
abstract = "Tardive dyskinesia can be suppressed by drugs that block dopaminergic receptors, but often at the cost of a concomitant increase in parkinsonism. Sulpiride (400-2100 mg/day), a selective type-2 dopamine receptor antagonist, was evaluated in a blind, placebo-controlled trial in 11 patients with tardive dyskinesia. It significantly (P",
keywords = "Dopamine receptors, Neuroleptics, Parkinsonism, Sulpiride, Tardive dyskinesia",
author = "Daniel Casey and Jes Gerlach and Hans Simmelsgaard",
year = "1979",
month = "11",
doi = "10.1007/BF00431993",
language = "English (US)",
volume = "66",
pages = "73--77",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Sulpiride in tardive dyskinesia

AU - Casey, Daniel

AU - Gerlach, Jes

AU - Simmelsgaard, Hans

PY - 1979/11

Y1 - 1979/11

N2 - Tardive dyskinesia can be suppressed by drugs that block dopaminergic receptors, but often at the cost of a concomitant increase in parkinsonism. Sulpiride (400-2100 mg/day), a selective type-2 dopamine receptor antagonist, was evaluated in a blind, placebo-controlled trial in 11 patients with tardive dyskinesia. It significantly (P

AB - Tardive dyskinesia can be suppressed by drugs that block dopaminergic receptors, but often at the cost of a concomitant increase in parkinsonism. Sulpiride (400-2100 mg/day), a selective type-2 dopamine receptor antagonist, was evaluated in a blind, placebo-controlled trial in 11 patients with tardive dyskinesia. It significantly (P

KW - Dopamine receptors

KW - Neuroleptics

KW - Parkinsonism

KW - Sulpiride

KW - Tardive dyskinesia

UR - http://www.scopus.com/inward/record.url?scp=0018702433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018702433&partnerID=8YFLogxK

U2 - 10.1007/BF00431993

DO - 10.1007/BF00431993

M3 - Article

C2 - 44375

AN - SCOPUS:0018702433

VL - 66

SP - 73

EP - 77

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1

ER -